Short- and mid-term outcomes in patients undergoing transcatheter aortic valve implantation in Poland in 2019–2023

Résumé fourni par la source

BACKGROUND: Transcatheter aortic valve implantation (TAVI) has become a cornerstone in the treatment of severe aortic stenosis, with expanding indications for lower-risk patients. However, real-world data, especially regarding post-discharge outcomes, from multicenter registries are scarce but needed. AIMS: To evaluate the in-hospital and mid-term outcomes of patients undergoing TAVI in all Polish centers between 2019 and 2023. MATERIAL AND METHODS: Clinical data were extracted from the Polish E-Health database of the National Health Fund. Procedures were identified using specific procedural codes. Long-term outcomes were established based on National Health Fund data, with outcome occurrence derived from the primary/secondary diagnoses for admissions during the one-year duration of follow-up, with a censoring date of December 31, 2023. RESULTS: Between 2019 and 2023, 11 351 TAVIs were performed in Poland. The in-hospital mortality rate was 2.9%. Of the total group, 7860 underwent the procedure between 2019 and 2022, providing a one-year follow-up to the censoring date. In those patients, the overall all-cause 1-year mortality was 12.7%, with higher rates among patients with atrial fibrillation, heart failure, and among men. Myocardial infarction occurred in 1.2%, stroke in 2.3%, and 23.3% patients required hospitalization for heart failure. The 12-month rate of cardiac implantable electronic device implantation was 11.8%. CONCLUSIONS: This study provides the first real-world TAVI outcomes in Polish patients based on the national, multicenter registry, showing an in-hospital mortality of 2.9% and a 12-month all-cause mortality of 12.7%. The 1-year outcomes of patients treated with TAVI in Poland are comparable to international registries.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.